Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Methicillin-Resistant Staphylococcus Aureus Infections Pipeline Highlights Update Report 2016 - Research and Markets

Research and Markets
Posted on: 28 Nov 16

Research and Markets has announced the addition of the "Methicillin-Resistant Staphylococcus Aureus Infections Pipeline Highlights - 2016 Update" drug pipelines to their offering.

Methicillin-Resistant Staphylococcus Aureus Infections Pipeline Highlights - 2016 Update, provides most up-to-date information on key pipeline products in the global Methicillin-Resistant Staphylococcus Aureus Infections market. It covers emerging therapies for Methicillin-Resistant Staphylococcus Aureus Infections in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Methicillin-Resistant Staphylococcus Aureus Infections pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Methicillin-Resistant Staphylococcus Aureus Infections pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Methicillin-Resistant Staphylococcus Aureus Infections pipeline products by the company.

Short-term Launch Highlights:

Find out which Methicillin-Resistant Staphylococcus Aureus Infections pipeline products will be launched in the US and Ex-US till 2019.

Key Topics Covered:

1. Methicillin-Resistant Staphylococcus Aureus Infections Pipeline by Stages

2. Methicillin-Resistant Staphylococcus Aureus Infections Pipeline by Drug Class

3. Methicillin-Resistant Staphylococcus Aureus Infections Pipeline by Company

4. Methicillin-Resistant Staphylococcus Aureus Infections Phase 3 Clinical Trial Insights

5. Methicillin-Resistant Staphylococcus Aureus Infections Phase 2 Clinical Trial Insights

6. Methicillin-Resistant Staphylococcus Aureus Infections Phase 1 Clinical Trial Insights

7. Methicillin-Resistant Staphylococcus Aureus Infections Preclinical Research Insights

8. Methicillin-Resistant Staphylococcus Aureus Infections Discovery Stage Insights

9. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/t9h6db/methicillinresist

View source version on businesswire.com: http://www.businesswire.com/news/home/20161128005609/en/

Business Wire
www.businesswire.com

Last updated on: 28/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.